THREE OF US ARE ACADEMIC RESEARCHERS AND CLINICIANS who rely on the generosity and support of funders for our work. In addition, we serve as consultants to companies and organizations that are engaged in Parkinson’s disease advocacy, care, education, or research. These relationships undoubtedly influence our perspectives. We have sought to minimize the potential for bias in our writing of Ending Parkinson’s Disease. For transparency, we disclose our relationships since 2017 here.
Ray Dorsey has served as a consultant to Abbott, AbbVie, American Well, Biogen, Clintrex, DeciBio, Denali Therapeutics, GlaxoSmithKline, Grand Rounds, Huntington Study Group, Mednick Associates, Michael J. Fox Foundation, Neurocrine, Olson Research Group, Origent, Pear Therapeutics, Prilenia, Putnam Associates, Roche, Sanofi, Sunovion Pharmaceuticals, and Voyager Therapeutics. He has received grant or research support from AbbVie, Acadia Pharmaceuticals, AMC Health, Biogen, Biosensics, Burroughs Wellcome Fund, Duke University, Food and Drug Administration, Greater Rochester Health Foundation, Huntington Study Group, Michael J. Fox Foundation, NIH, Nuredis Pharmaceuticals, Patient-Centered Outcomes Research Institute, Pfizer, Safra Foundation, Sage Bionetworks, and the University of California, Irvine. He receives compensation from Karger Publications for serving as the editor of the journal Digital Biomarkers. He has ownership interests in Grand Rounds (a second-opinion service).
Michael Okun serves as the medical director for the Parkinson’s Foundation, is an associate editor for JAMA Neurology and the New England Journal of Medicine Journal Watch Neurology. He has received research grants from the Bachmann-Strauss Foundation, Michael J. Fox Foundation, NIH, Parkinson Alliance, Parkinson’s Foundation, Smallwood Foundation, Tourette Association of America, and UF Foundation. His deep brain stimulation research is supported by two grants from the NIH (R01NR014852 and R01NS096008), and he is on mentorship committees for several NIH career-development awards. He also has received royalties for publications for books on Parkinson’s disease and other movement disorders from Amazon, Books4Patients, Cambridge, Demos, Manson, and Smashwords. He has participated in continuing medical education and other educational activities on movement disorders sponsored by the American Academy of Neurology, Henry Stewart, the International Parkinson Disease and Movement Disorder Society, MedEdicus, MedNet, PeerView, Prime, QuantiaMD, Vanderbilt University, and WebMD/Medscape. The University of Florida receives grants from Abbott, AbbVie, Allergan, Boston Scientific, and Medtronic for work that Dr. Okun helps lead. He has also participated in, but not received honoraria for his role as an investigator for, several NIH-, foundation-, and industry-sponsored clinical trials.
Bas Bloem has received honoraria for serving on the scientific advisory board for AbbVie, Biogen, UCB, Walk with Path, and Zambon, has received fees for speaking at conferences from AbbVie, Bial, GE Healthcare, Roche, and Zambon, and has received research support from the Netherlands Organization for Scientific Research, Michael J. Fox Foundation, UCB, AbbVie, Stichting ParkinsonFonds, Hersenstichting Nederland, Stichting Parkinson Nederland, Parkinson’s Foundation, Verily Life Sciences, Horizon 2020, Topsector Life Sciences and Health, and Parkinson Vereniging.
Todd Sherer has nothing to disclose.